Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas

Journal of Neuropathology and Experimental Neurology

Volumn 64, Issue 6, 2005, Pages 479-489

  Ohgaki, Hiroko ^a   Kleihues, Paul ^b  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Astrocytoma; EGFR amplification; Glioblastoma; LOH 10; LOH 19q; LOH 1p; Oligodendroglioma; P16INK4a deletion; Population based study; PTEN mutation; TP53 mutation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P16INK4A; PROTEIN P53;

ADULT; AGED; ASTROCYTOMA; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SURVIVAL; CHROMOSOME 10Q; CHROMOSOME 19Q; CHROMOSOME 1P; FEMALE; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OLIGODENDROGLIOMA; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 20344407807     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/64.6.479     Document Type: Review

References (67)

1. Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-18
2. Weller M, Muller B, Koch R, Bamberg M, Krauseneck P. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 2003;21:3276-84
3. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6:217-24
4. Kleihues P, Ohgaki H. Phenotype vs genotype in the evolution of astrocytic brain tumors. Toxicol Pathol 2000;28:164-70
5. Ohgaki H, Kleihues P. Genetic basis of gliomas progression. Proc Jpn Acad 2003;79:78-85
6. Burkhard C, Di Patre PL, Schüler D, et al. A population-based study on the incidence and survival of patients with pilocytic astrocytoma. J Neurosurg 2003;98:1170-74
7. Okamoto Y, Di Patre PL, Burkhard C, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade astrocytomas and oligodendrogliomas. Acta Neuropathol 2004;108:49-56
8. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: A population-based study. Cancer Res 2004;64:6892-99
9. Kleihues P, Cavenee WK (eds). WHO Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System. Lyon, IARC Press, 2000
10. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of rumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215-25
11. Central Brain Tumor Registry of the United States (CBTRUS; http://www.cbtrus.org). 2002
12. McCarthy BJ, Surawicz T, Bruner JM, Kruchko C, Davis F. Consensus conference on brain tumor definition for registration. November 10;2000. Neuro-oncol 2002;4:134-45
13. Scott JN, Rewcastle NB, Brasher PM, et al. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 1999;46:183-88
14. Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H. Role of gemistocytes in astrocytoma progression. Lab Invest 1997;76:277-84
15. Onda K, Davis RL, Wilson CB, Hoshino T. Regional differences in bromodeoxyuridine uptake, expression of Ki-67 protein, and nucleolar organizer region counts in glioblastoma multiforme. Acta Neuropathol (Berl) 1994;87:586-93
16. Reis RM, Kara A, Kleihues P, Ohgaki H. Genetic evidence of the neoplastic nature of gemistocytes in astrocytomas. Acta Neuropathol 2001;102:422-25
17. Watanabe K, Peraud A, Gratas C, Wakai S, Kleihues P, Ohgaki H. p53 and PTEN gene mutations in gemistocytic astrocytomas. Acta Neuropathol 1998;95:559-64
18. Maintz D, Fiedler K, Koopmann J. et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997;56:1098-1104
19. Huang H, Okamoto Y, Yokoo H, et al. Gene Expr profiling and subgroup identification of oligodendrogliomas. Oncogene 2004;23:6012-22
20. Dropcho EJ, Soong SJ. The prognostic impact of prior low-grade histology in patients with anaplastic gliomas: A case-control study. Neurology 1996;47:684-90
21. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005;109:93-108
22. Louis DN, von Deimling A, Chung RY, et al. Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 1993;52:31-38
23. Peraud A, Ansari H, Bise K, Reulen HJ. Clinical outcome of supratentorial astrocytoma WHO grade II. Acta Neurochir (Wien) 1998;140:1213-22
24. Rasheed BK, McLendon RE, Friedman HS, et al. Chromosome 10 deletion mapping in human gliomas: A common deletion region in 10q25. Oncogene 1995;10:2243-46
25. Karlbom AE, James CD, Boethius J, et al. Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Hum Genet 1993;92:169-74
26. Ichimura K, Schmidt EE, Miyakawa A, Goike HM, Collins VP. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer 1998;22:9-15
27. Fults D, Pedone CA, Thompson GE, et al. Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMA1, FAS, and MXI1 in human glioblastoma multiforme. Int J Oncol 1998;12:905-10
28. Schmidt MC, Antweiler S, Urban N, et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002;61:321-28
29. Tada K, Shiraishi S, Kamiryo T, et al. Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: Correlation with patient age and survival. J Neurosurg 2001;95:651-59
30. Terada K, Tamiya T, Daido S, et al. Prognostic value of loss of heterozygosity around three candidate tumor suppressor genes on chromosome 10q in astrocytomas. J Neurooncol 2002;58:107-14
31. Simpson L, Parsons R. PTEN: Life as a tumor suppressor. Exp Cell Res 2001;264:29-41
32. Dahia PL. PTEN, a unique tumor suppressor gene. Endocr Relat Cancer 2000;7:115-29
33. Knobbe CB, Merlo A, Reifenberger G. Pten signaling in gliomas. Neurooncol 2002;4:196-211
34. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001;93:1246-56
35. Backlund LM, Nilsson BR, Goike HM, et al. Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN. Clin Cancer Res 2003;9:4151-58
36. Bogler O, Huang HJ, Kleihues P, Cavenee WK. The p53 gene and its role in human brain tumors. Glia 1995;15:308-27
37. Simmons ML, Lamborn KR, Takahashi M, et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 2001;61:1122-28
38. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: More than just expression? Oncologist 2002;7 Suppl 4:31-39
39. Hurtt MR, Moossy J, Donovan Peluso M, Locker J. Amplification of epidermal growth factor receptor gene in gliomas: Histopathology and prognosis. J Neuropathol Exp Neurol 1992;51:84-90
40. Torp SH, Helseth E, Dalen A, Unsgaard G. Relationships between Ki-67 labelling index, amplification of the epidermal growth factor receptor gene, and prognosis in human glioblastomas. Acta Neurochir (Wien) 1992;117:182-86
41. Huncharek M, Kupelnick B. Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol Res 2000;12:107-12
42. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63:6962-70
43. Batchelor TT, Betensky RA, Esposito JM, et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 2004;10:228-33
44. INK4a and the control of cellular proliferative life span. Carcinogenesis 1999;20:921-26
45. Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: Progress and puzzles. Curr Opin Genet Dev 2003;13:77-83
46. Arf deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 2001;11:159-68
47. Kamiryo T, Tada K, Shiraishi S, et al. Analysis of homozygous deletion of the p16 gene and correlation with survival in patients with glioblastoma multiforme. J Neurosurg 2002;96:815-22
48. Labuhn M, Jones G, Speel EJ, et al. Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas. Oncogene 2001;20:1103-9
49. Fujisawa H, Kurrer M, Reis RM, Yonekawa Y, Kleihues P, Ohgaki H. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with LOH on chromosome 10q25-qter. Am J Pathol 1999;155:387-94
50. Kang W, Reid KB. DMBT1, a regulator of mucosal homeostasis through the linking of mucosal defense and regeneration? FEBS Lett 2003;540:21-25
51. INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas. Int J Cancer 1997;73:57-63
52. Hayashi Y, Ueki K, Waha A, Wiestler OD, Louis DN, von Deimling A. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 1997;7:871-75
53. Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999;354:34-39
54. Nygaard R, Garwicz S, Haldorsen T, et al. Second malignant neoplasms in patients treated for childhood leukemia. A population-based cohort study from the Nordic countries. The Nordic Society of Pediatric Oncology and Hematology (NOPHO). Acta Paediatr Scand 1991;80:1220-28
55. Hussain SP, Harris CC. p53 mutation spectrum and load: The generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat Res 1999;428:23-32
56. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991;350:427-28
57. Pfeifer GP, Hainaut P. On the origin of G → T transversions in lung cancer. Mutat Res 2003;526:39-43
58. Ohgaki H, Vital A, Kleihues P Hainaut P. Li-Fraumeni syndrome and TP53 germline mutations. In: Kleihues P, Cavenee WK, eds. WHO Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press, 2000;231-34
59. Ohshima H, Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: Possible role of nitric oxide in carcinogenesis. Mutat Res 1994;305:253-64
60. Tornaletti S, Pfeifer GP. Complete and tissue-independent methylation of CpG sites in the p53 gene: Implications for mutations in human cancers. Oncogene 1995;10:1493-99
61. Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H. Promoter hypermethylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C → A:T mutations of the TP53 rumor suppressor gene. Carcinogenesis 2001;22:1715-19
62. 6-alkylguanine by alkyltransferases. Mutat Res 2000;462:83-100
63. 6-methylguanine-DNA methyltransferase in histologically normal brain adjacent to primary human brain tumors. Proc Natl Acad Sci USA 1996;93:6941-46
64. Lijinsky W. Chem Biol of N-nitroso Compounds. New York: Cambridge University Press, 1992
65. De Bont R, van Larebeke N. Endogenous DNA damage in humans: A review of quantitative data. Mutagenesis 2004;19:169-85
66. Kang H, Konishi C, Kuroki T, Huh N. Detection of O6-methylguanine, O4-methylthymine and O4-ethylthymine in human liver and peripheral blood leukocyte DNA. Carcinogenesis 1995;16:1277-80
67. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S. ICD-O International Classification of Diseases for Oncology, 3rd Edition, Geneva:World Health Organization, 2000